<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2093951/" ref="ordinalpos=472&amp;ncbi_uid=1098163&amp;link_uid=PMC2093951" image-link="/pmc/articles/PMC2093951/figure/F9/" class="imagepopup">Fig. 9. Model for the inhibitory effect of VIP on IL-12 <span class="highlight" style="background-color:">signaling</span>.  From: A NOVEL VIP <span class="highlight" style="background-color:">SIGNALING</span> <span class="highlight" style="background-color:">PATHWAY</span> IN T CELLS cAMP-&gt; Protein Tyrosine Phosphatase (SHP-2?)-&gt;JAK2/STAT4-&gt;Th1 differentiation. </a></div><br /><div class="p4l_captionBody">VIP acting through the VPAC1/2/ receptors activates adenylate cyclase resulting in the activation of PKA. PKA phosphorylates SHP-2, a protein tyrosine phosphatase which in turn acts on Jak2 and possibly directly on STAT4. Dephosphorylation of Jak2 and STAT4 interrupts the IL-12 signaling pathway and prevents the expression of genes involved in Th1 differentiation and function.</div></div>